Colorectal cancer consensus molecular subtypes. Number 1, 2020
View in PDF Number of views: 0 Living forever is a beautiful vision that human being has been pursuing.
With the development of science and technology, an increasing number of approaches have been emerging for repairing and regenerating the damaged organs, such as cell therapy, gene therapy and transplant etc.
However, the side effects of these methods limit their clinical use.
For example, myoblast transplantation leads to an increase in number of early postoperative arrhythmic events 1. Therefore, it has a long way to use these approaches for colorectal cancer consensus molecular subtypes therapy in a short-term and it is urgent to look for secure effective strategies.
Colorectal cancer consensus molecular subtypes. Conținutul Rom J Morphol Embryol ; 60 1 : The clinical and histological classification of periocular basal cell carcinoma pBCC is essential in order to establish the risk of recurrence and to compare the results of the treatment. Until now, there is no unitary histological classification of pBCC.
Recently, extracellular vesicles EVs have attracted extensive interests as a potential therapeutic strategy of diseases such as cancer, cardiovascular diseases etc. A growing number of investigations demonstrate that various engineered EVs can repair the damaged tissue in vivo 2.
- Romjoh 1 (1) by Innovation in Health Center - Issuu
- Archive issue | RJME
This editorial highlights 6 selected papers dedicated to the engineered extracellular vesicles as well as nanoparticles, including: 1 classical strategies for modifying EVs; 2 the roles of engineered EVs in treatment. Besides, the outlook for engineered EVs has been briefly discussed.
Role of Molecular Testing in CRC Management
To improve the efficiency of EVs as well as targeted tissue retention, several investigations were performed. This approach laid the foundation for cell and cardiac-specific EVs delivery, which gives a reference for studying targeted-EV.
Interestingly, Tang et al came up with a novel idea based on the recruitment of platelets by injured endothelial cells 4. These authors decorated platelet-microvesicles inside of platelet, similar with EVs on the surface of cardiosphere-derived cardiac stem cells CSCswhich significantly increased the retention in the heart. This manipulation approach is safe and straightforward, which opens novel insights into targeted-EVs for therapy.
Recently, Liming et al used an adhesive hydrogel to enhance the retention of EVs 5. The Exo-pGel presents a promising strategy for preclinical treatment. It has been well established that the engineered EVs have great potential for disease treatment in animal models.
This work demonstrates a novel approach for increasing delivery of myocardial infarction colorectal cancer consensus molecular subtypes. Liu et al reported that EVs loading with novel complex hydrogels can promote wounds healing, which provides another effective hydrogel strategy for engineering EVs 7.
Li et al investigated the roles of Exo-pGel in treatment of spinal cord injury.
- Journal archive. Articles: ARCHIVES OF THE BALKAN MEDICAL UNION
- Acta Clin Belg ; :Oct
The Exo-pGel significantly promoted nerve recovery via inhibiting oxidative stress and inflammation5. Besides, Chuanjiang He et al give an insight into how EVs engineered as powerful tools in translational medicine 8.
Molecular biology of cholesteatoma Alma Maniu, Oana Harabagiu, Maria Perde Schrepler, Andreea Catana, Bogdan Fanuta, Carmen Aurelia Mogoanta Cholesteatoma is a non-neoplastic, keratinizing lesion, characterized by the proliferation of epithelium with aberrant micro-architecture into the middle ear and mastoid cavity. The exact pathogenic molecular mechanisms behind the formation and propagation of cholesteatoma remain unclear. Immunohistochemical examinations of the matrix and perimatrix have considerably improved the knowledge of cholesteatoma pathogenesis.
Notably, more preclinical investigations and clinical trials are still needed to elucidate the possibility of engineered EVs and nanoparticles in human diseases treatment.
